TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7988629

Group type: EXPERIMENTAL
Intervention: Diltiazem CR 120 mg b.i.d. for 4 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Plain diltiazem tablets 60 mg q.i.d. for 4 weeks
Number of subjects: 23
Study: 2522147

Group type: EXPERIMENTAL
Intervention: Intramuscular route (IM group)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Intradermal route (ID group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 165
Study: 31100085

Group type: EXPERIMENTAL
Intervention: Best Possible Self condition
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: One’s best self in the present
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: One’s best self in the past
Number of subjects: 78
Study: 28476479

Group type: EXPERIMENTAL
Intervention: LUCAS‐2 mechanical device for CPR
Number of subjects: 4471

Group type: COMPARATOR
Intervention: Manual chest compressions (control)
Number of subjects: 4471
Study: 25319535

Group type: EXPERIMENTAL
Intervention: Training in the use of a BPSD-structured clinical protocol, plus external clinical support
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Workshop on BPSD, plus external clinical support
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Training in the use of the structured clinical protocol alone
Number of subjects: 204

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 204
Study: 23352081

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied to extraction sockets immediately after extraction
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no PRP applied to extraction sockets)
Number of subjects: 25
Study: 20651013

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Traditional Exercise Program (TEP)
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Both CSEP and TEP
Number of subjects: 1141
Study: 18047764

Group type: EXPERIMENTAL
Intervention: Anticonvulsant mood stabilizers (carbamazepine, valproic acid)
Number of subjects: 7
Study: 16879470

Group type: EXPERIMENTAL
Intervention: Controlled hypotension (CH) induced with esmolol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acute normovolemic hemodilution (ANH) only
Number of subjects: 56
Study: 12748244

Group type: EXPERIMENTAL
Intervention: 250 mg/d gefitinib
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 500 mg/d gefitinib
Number of subjects: 210
Study: 10817716

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 160 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 800 mg
Number of subjects: 0
Study: 8647328

Group type: EXPERIMENTAL
Intervention: Semantic-pragmatic language disorder group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-level autism group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of normal children
Number of subjects: 0
Study: 2052460

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Combination of aminophylline and doxapram
Number of subjects: 2
Study: 7083219

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g orally at 12, 18, 24, 36, and 48 hours)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no activated charcoal)
Number of subjects: 15
Study: 31206787

Group type: EXPERIMENTAL
Intervention: Home-based NB-UVB phototherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital-based NB-UVB phototherapy
Number of subjects: 100
Study: 30519898

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Number of subjects: 317

Group type: COMPARATOR
Intervention: Oral estrogen
Number of subjects: 317
Study: 28560383

Group type: EXPERIMENTAL
Intervention: 30 mg genistein daily for 3-6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules daily for 3-6 weeks
Number of subjects: 0
Study: 24994573

Group type: EXPERIMENTAL
Intervention: Postnatal psychoeducation programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: Routine postnatal care
Number of subjects: 180
Study: 23432415

Group type: EXPERIMENTAL
Intervention: Netazepide 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netazepide (various doses 5, 10, 25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netazepide (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21491420

Group type: EXPERIMENTAL
Intervention: HPV vaccine
Number of subjects: 865

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study: 19111850

Group type: EXPERIMENTAL
Intervention: Drug and nutritional supplements trials
Number of subjects: 7941

Group type: EXPERIMENTAL
Intervention: Quality of evidence from randomized controlled trials
Number of subjects: 7941
Study: 17258381

Group type: EXPERIMENTAL
Intervention: TOT surgery performed by an experienced surgeon (Group 1, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TOT surgery performed by a senior resident under supervision (Group 2, n=30)
Number of subjects: 60
Study: 14987305

Group type: EXPERIMENTAL
Intervention: Mequitazine 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mequitazine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mequitazine 15 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 6 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11276370

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) + Granulocyte Colony-Stimulating Factor (GCSF)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GM-CSF followed by GCSF
Number of subjects: 35

Group type: COMPARATOR
Intervention: All arms (A, B, C)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Poor mobilizers (failed to mobilize 0.4 x 10(6) CD34(+) cells/kg in 2 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Successful mobilizers (mobilized 0.4 x 10(6) CD34(+) cells/kg in 2 days)
Number of subjects: 35
Study: 9135927

Group type: EXPERIMENTAL
Intervention: Miglitol (50 mg t.i.d., followed by 100 mg t.i.d.)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Glibenclamide (3.5 mg q.d/b.i.d.)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 7970848

Group type: COMPARATOR
Intervention: Prophylactic co-trimoxazole
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Counts of > 20 bacteria adherent to bladder cells
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (0.1, 0.5, 1.0 micrograms/ml)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 14
Study: 3315645

Group type: EXPERIMENTAL
Intervention: 12 weeks daily PMR instruction provided in class for academic credit (n = 51)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control condition (n = 59)
Number of subjects: 1400
Study: 28787759

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) at 0.25 mg per kg of patient weight injected intraoperatively after explorative laparotomy before CS.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) for detecting tumor cells in post-NAC scars.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) for detecting tumor cells in scars.
Number of subjects: 20
Study: 27097736

Group type: EXPERIMENTAL
Intervention: High variety support exercise program
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low variety support exercise program
Number of subjects: 121
Study: 24612164

Group type: EXPERIMENTAL
Intervention: e-learning condition
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: integral condition
Number of subjects: 3784
Study: 22587483

Group type: COMPARATOR
Intervention: rosiglitazone (4-8 mg/day)
Number of subjects: 373

Group type: COMPARATOR
Intervention: pioglitazone (15-45 mg/day)
Number of subjects: 373

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 373
Study: 19922492

Group type: EXPERIMENTAL
Intervention: Cylindrical implant (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tapered implant (group B)
Number of subjects: 0
Study: 17448971

Group type: EXPERIMENTAL
Intervention: Iron ferrous sulphate (256 mg/day; 80 mg of Fe(2+)), vitamin C (1000 mg/day), and folic acid (5mg/day) during the 30‐45 days preceding surgery (Group 2)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 156
Study: 15519131

Group type: EXPERIMENTAL
Intervention: 500 mg LEV
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2000 mg LEV
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12054147

Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg iv weekly for three consecutive doses, followed by one infusion every 3 weeks for a total of 24 infusions)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 200
Study: 9754184

Group type: EXPERIMENTAL
Intervention: Hyperopic PRK with the VISX STAR Excimer Laser System
Number of subjects: 38
Study: 8160979

Group type: EXPERIMENTAL
Intervention: Forced-air warming during surgery
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional warmed cotton blankets
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Forced-air warming during and after surgery
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Postoperative warming
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 127
Study: 3258001

Group type: EXPERIMENTAL
Intervention: Solarium radiation (not filtered through Mylar sheeting) for 30 min on 12 consecutive days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Solarium radiation (filtered through 0.1 mm thick Mylar sheeting) for 30 min on 12 consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated group (no exposure to solarium radiation)
Number of subjects: 10
Study: 28434415

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) behavioral parent training program
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY)
Number of subjects: 387
Study: 27546308

Group type: EXPERIMENTAL
Intervention: High-Fe formula (6.6 mg Fe/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low-Fe formula (1.3 mg Fe/d)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fe drops (6.6 mg Fe/d)
Number of subjects: 72
Study: 24709874

Group type: EXPERIMENTAL
Intervention: Specific resistance training for the neck/shoulder muscles three times a week
Number of subjects: 131

Group type: COMPARATOR
Intervention: Advice to stay active (Control group)
Number of subjects: 131
Study: 23582414

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Optimal medical therapy (MED)
Number of subjects: 454
Study: 20836606

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning using positive social stimuli (pictures of smiling faces) linked to pictures of their own bodies
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control condition with random association of pictures of their own body and control bodies with positive, neutral, and negative social stimuli
Number of subjects: 54
Study: 19127917

Group type: EXPERIMENTAL
Intervention: Intradermal needle combined with Tuina therapy
Number of subjects: 150
Study: 16368842

Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine at 37 degrees C
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hyperbaric 0.5% bupivacaine at 25 degrees C
Number of subjects: 36
Study: 15014407

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (aspirin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rofecoxib (Vioxx)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 36
Study: 11704116

Group type: EXPERIMENTAL
Intervention: 150 IU of recombinant FSH
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 250 IU of recombinant FSH
Number of subjects: 404
Study: 9632034

Group type: EXPERIMENTAL
Intervention: Once-daily venlafaxine (37.5 mg daily, increased up to 225 mg daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Twice-daily venlafaxine (37.5 mg daily, increased up to 225 mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 48
Study: 7890902

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a therapy
Number of subjects: 14
Study: 3223118

Group type: EXPERIMENTAL
Intervention: Prednisolone (additional to ampicilline and metronidazol for 10 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ampicilline and metronidazol (without prednisolone)
Number of subjects: 59
Study: 28401595

Group type: EXPERIMENTAL
Intervention: Cognitive music training (12 bi-weekly 70-min sessions)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (12 bi-weekly 45-min sessions of gymnastic activities)
Number of subjects: 35
Study: 28493347

Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Delayed loading
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early loading
Number of subjects: 39
Study: 23666533

Group type: EXPERIMENTAL
Intervention: Laser (Ul, N=20 and Ll, N=20)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Up, N=20 and Lp, N=20)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Uc, N=20 and Lc, N=20)
Number of subjects: 120
Study: 22795720

Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 9406

Group type: COMPARATOR
Intervention: Delayed provisional eptifibatide
Number of subjects: 9406
Study: 21616512

Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy (5 mU·kg(‐1)·min(‐1) starting at skin incision)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard metabolic care (target glycemia 6.0‐10.0 mmol/L, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy
Number of subjects: 20
Study: 18431002

Group type: EXPERIMENTAL
Intervention: Experimental group (EG) received four-day-in-a-row treatment with 10 degrees rightward deviating prisms.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG) received four-day-in-a-row placebo treatment.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experimental group (EG) at one month post-treatment.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG) at one month post-treatment.
Number of subjects: 16
Study: 16918222

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injections in ankle flexors, hamstrings, and adductors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injections
Number of subjects: 0
Study: 12787037

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinolone acetonide in orabase (FAO)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.1% fluocinolone acetonide solution (FAS)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both 0.1% fluocinolone acetonide solution and in orabase (FAS/FAO)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97
Study: 10735680

Group type: EXPERIMENTAL
Intervention: Aprotinin (200,000 KIU bolus + 100,000 KIU/h for 8 hours)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 9186336

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate
Number of subjects: 52

Group type: COMPARATOR
Intervention: High energy microwave thermotherapy
Number of subjects: 52
Study: 1550278

Group type: EXPERIMENTAL
Intervention: Transaortic plexus block
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Classic retrocrural block
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bilateral chemical splanchnicectomy
Number of subjects: 61
Study: 3924533

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg qid) with Misoprostol (25 micrograms qid)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aspirin (650 mg qid) with Placebo
Number of subjects: 32
Study: 31719075

Group type: EXPERIMENTAL
Intervention: Timed Up-and-Go (TUG)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Repeated Chair Stands (RCS)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Walking Speed Tests
Number of subjects: 128
Study: 27797014

Group type: EXPERIMENTAL
Intervention: Gain-framed (GF) message
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Loss-framed (LF) message
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Self-regulatory efficacy-enhancing (SRE) message
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Gain-framed plus SRE (GF + SRE) message
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Loss-framed plus SRE (LF + SRE) message
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 732
Study: 25478993

Group type: EXPERIMENTAL
Intervention: MOO group
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: MHO group
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: MONO group
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: MHNO group
Number of subjects: 1302

Group type: COMPARATOR
Intervention: All groups (MHNO to MOO)
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: TNF‐α
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: hs‐CRP
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Oxidized LDL
Number of subjects: 1302
Study: 24112149

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (5 µg) via Respimat
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 21821304

Group type: EXPERIMENTAL
Intervention: 16Gy boost dose
Number of subjects: 1603

Group type: COMPARATOR
Intervention: No boost
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: High grade invasive tumors
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Nomogram including histologic grade, DCIS, tumor diameter, age, tamoxifen, chemotherapy, and boost
Number of subjects: 1603
Study: 19772177

Group type: EXPERIMENTAL
Intervention: 5% dextrose in 0.45% NaCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 60
Study: 16769915

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CCAB)
Number of subjects: 120
Study: 15170905

Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with sulfasalazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lefunomide in combination with etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lefunomide in combination with anakinra
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leflunomide monotherapy
Number of subjects: 0
Study: 12575608

Group type: EXPERIMENTAL
Intervention: Astragalus saponin (AS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Burn control group
Number of subjects: 80
Study: 9040911

Group type: EXPERIMENTAL
Intervention: Modified obstetrics curriculum at McGill University (MG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No modifications at University of Montreal (UM) (control group)
Number of subjects: 57
Study: 8176256

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg taken each morning for 6 days before cyclosporin doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclosporin 300 mg taken alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg taken on the seventh day with cyclosporin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg taken with cyclosporin
Number of subjects: 20
Study: 3579464

Group type: EXPERIMENTAL
Intervention: Loperamide (0.5 mg/kg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (5 controls)
Number of subjects: 19
Study: 30445454

Group type: EXPERIMENTAL
Intervention: Brief incubation (0.3-1.2 million motile sperm/ml for 3-4 hours)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard incubation (0.3-1.2 million motile sperm/ml for 20 hours)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Brief incubation
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard incubation
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 320
Study: 28581367

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON
Number of subjects: 12
Study: 25895588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + modified release nifedipine 30 mg
Number of subjects: 100
Study: 25154152

Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol followed by 3 tablets of 200 microg misoprostol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (3 tablets)
Number of subjects: 150
Study: 22484899

Group type: EXPERIMENTAL
Intervention: GuttaFlow
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zinc-oxide eugenol sealer and gutta-percha cone using cold lateral obturation technique
Number of subjects: 10
Study: 19835463

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control (oral glucose-lowering drugs excluding thiazolidinediones)
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control
Number of subjects: 587